Instrument Inactif

Communiqués GW PHARMACEUTICALS OTC Markets

Actions

GWPRF

GB0030544687

Recherche biotechnologique et médicale

Communiqués

05/05/21	GW PHARMACEUTICALS PLC : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
05/05/21	GW Pharmaceuticals : Jazz Pharmaceuticals Completes Acquisition of GW Pharmaceuticals plc	PR
03/05/21	GW PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ
29/04/21	GW Pharmaceuticals : recognised for leadership in prescription cannabis-based medicines with prestigious Queen's Award for Enterprise in Innovation	AQ
29/04/21	GW Pharmaceuticals : Highest British business award goes to cannabis drug developer, GW Pharmaceuticals	AQ
29/04/21	GW Pharmaceuticals recognised for leadership in prescription cannabis-based medicines with prestigious Queen’s Award for Enterprise in Innovation	GL
26/04/21	GW PHARMACEUTICALS PLC : Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
23/04/21	GW Pharmaceuticals Shareholders Approve Acquisition by Jazz Pharmaceuticals	GL
21/04/21	GW Pharmaceuticals : receives European Commission approval for EPIDYOLEX (cannabidiol) for the treatment of seizures associated with tuberous sclerosis complex	AQ
20/04/21	GW PHARMACEUTICALS PLC : Other Events (form 8-K)	AQ
20/04/21	GW Pharmaceuticals receives European Commission approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures associated with tuberous sclerosis complex	GL
14/04/21	GW PHARMACEUTICALS PLC : Other Events (form 8-K)	AQ
13/04/21	GW Pharmaceuticals and U.S. Subsidiary Greenwich Biosciences to Present Data at the 2021 American Academy of Neurology (AAN) Annual Meeting	GL
23/03/21	GW PHARMACEUTICALS PLC : Other Events (form 8-K)	AQ
01/03/21	GW Pharmaceuticals : receives positive CHMP opinion for EPIDYOLEX for use as treatment of seizures associated with Tuberous Sclerosis Complex	AQ
26/02/21	GW PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	AQ
26/02/21	GW Pharmaceuticals receives positive CHMP opinion for EPIDYOLEX® (cannabidiol) for use as treatment of seizures associated with Tuberous Sclerosis Complex	GL
24/02/21	GW Pharmaceuticals : Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2020 Financial Results	AQ
16/02/21	GW PHARMACEUTICALS PLC : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)	AQ
16/02/21	GW Pharmaceuticals : Reports Fourth Quarter and Year-End 2020 Financial Results and Operational Progress	AQ
13/02/21	SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of GW Pharmaceuticals plc - GWPH	PR
05/02/21	GW Pharmaceuticals : Jazz to acquire GW Pharmaceuticals for $7.2 billion	AQ
04/02/21	GW PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of GW Pharmaceuticals plc - GWPH	BU
04/02/21	GW Pharmaceuticals : Jazz Pharmaceuticals to Acquire GW Pharmaceuticals plc, Creating an Innovative, High-Growth, Global Biopharma Leader	AQ
03/02/21	GW PHARMACEUTICALS PLC : Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ